Core Viewpoint - The 2025 Nobel Prize in Chemistry has been awarded to Susumu Kitagawa, Richard Robson, and Omar M. Yaghi for their contributions to the development of metal-organic frameworks [1] Group 1: Awardees Background - Susumu Kitagawa, born in 1951, is affiliated with Kyoto University and focuses on the fundamental research and application development of metal-organic framework materials [3] - Richard Robson, born in 1937, works at the University of Melbourne and has made significant contributions to the theoretical foundations of metal-organic frameworks [6] - Omar M. Yaghi is a professor at the University of California, Berkeley, known for major breakthroughs in the synthesis methods and practical applications of metal-organic frameworks [9] Group 2: Nobel Prize History - As of October 2024, the Nobel Prize in Chemistry has been awarded 116 times to 197 recipients, with 63 awards given to individuals, 25 shared by two, and 28 shared by three [12] - Notable statistics include 8 years where the award was not given, 9 years of delayed awards, and the recognition of 8 female laureates [12] - The youngest laureate was Jean Frédéric Joliot-Curie, who won at age 35 in 1935, while the oldest was John Goodenough, awarded at age 97 for his work on lithium batteries [12] Group 3: Recent Nobel Prize Winners - In 2024, half of the prize was awarded to David Baker, with the other half shared by Demis Hassabis and John Jumper for their contributions to protein design and structure prediction [13] - The 2023 prize was awarded to Mogi Bawendi, Louis Brus, and Alexei Ekimov for their discovery and synthesis of quantum dots [14] - In 2022, the award went to Carolyn Bertozzi, Morten Meldal, and Carolyn Bertozzi for their work in click chemistry and bioorthogonal chemistry [15]

（原标题：刚刚，2025年诺贝尔化学奖揭晓！） 瑞典皇家科学院当地时间10月8日宣布，将2025年诺贝尔化学奖授予北川进 （Susumu Kitagawa）、理 查德·罗布森（Richard Robson）和奥马尔·M·亚吉 （Omar M. Yaghi），以表彰他们"在金属有机框架领 域的发展"。 北川进 （Susumu Kitagawa） 理查德·罗布森（Richard Robson） 奥马尔·M·亚吉 （Omar M. Yaghi） 截至2024年10月，诺贝尔化学奖已经颁发116次，有197位获得者，其中63次由1人获得，25次由2人分 享，28次由3人共享。其中有8年因故停发；有9年延迟一年颁发；2位两次获奖；8位女性获奖；一对夫 妻获奖；一对母女获奖。 最年长的诺贝尔化学奖是美国科学家约翰·古迪纳夫，时年97岁。他被誉为"锂电池之父"，他的研究彻 底改变了手机、电脑以及电动汽车的充电方式。2023年6月，古迪纳夫去世，享年100岁。 近三年诺贝尔化学奖获奖情况： 2024年一半授予大卫·贝克，另一半共同授予德米斯·哈萨比斯和约翰·江珀，以分别表彰他们在蛋白质设 计和蛋白质结构预测领域的贡献。 20 ...

Core Insights - Carolyn Bertozzi, a Nobel laureate and prominent scientist, emphasizes the parallels between music and science, highlighting the importance of collaboration and listening in both fields [2] - Bertozzi has made significant advancements in bioorthogonal chemistry, which has implications for cancer treatment, particularly in targeted imaging and drug delivery [2][5] - The collaboration with Henlius, a Shanghai-based biopharmaceutical company, aims to initiate the first human clinical trials for a new cancer immunotherapy in the coming year [3][6] Group 1: Scientific Contributions - Bertozzi's research focuses on the role of sialic acid on cancer cells, which helps them evade the immune system; her team developed an antibody drug to target and eliminate this disguise [5][6] - The concept of bioorthogonal chemistry allows for the modification of specific biomolecules without disrupting natural biological processes, enhancing the development of therapeutic drugs [6] - The new immunotherapy, named EAGLE, shows promise in treating high mutation cancers like melanoma and lung cancer, with successful tests in animal models [6][7] Group 2: Collaboration and Diversity - Bertozzi advocates for diversity in scientific research teams, believing that varied backgrounds enhance problem-solving and research priorities [7][8] - She emphasizes the importance of student contributions to research, stating that many of her significant ideas originated from her students [8] - The collaboration with Henlius represents a strategic partnership aimed at advancing cancer treatment through innovative therapies [3][6]

Core Viewpoint - The article highlights the significant breakthroughs in cancer treatment through the work of Carolyn Ruth Bertozzi, particularly in the field of bioorthogonal chemistry, which enables targeted imaging and drug delivery for cancer cells, potentially revolutionizing cancer immunotherapy [4][6][8]. Group 1: Breakthroughs in Cancer Treatment - Carolyn Bertozzi's research focuses on the role of sialic acid on cancer cells, which helps them evade the immune system. Her team developed an antibody drug that removes this "camouflage," making cancer cells more recognizable to immune cells [6][7]. - The concept of bioorthogonal chemistry, introduced by Bertozzi, allows for specific tracking and modification of biological molecules without disrupting natural processes, facilitating the development of effective cancer therapies [7][8]. - The collaboration with Henlius (Shanghai Henlius Biopharma) aims to initiate the first human clinical trials for a dual-function sialic acid enzyme fusion protein therapy next year [4][8]. Group 2: Importance of Collaboration and Diversity - Bertozzi emphasizes the value of diverse backgrounds in scientific research, sharing her experiences of recruiting students from various institutions and disciplines to enhance creativity and problem-solving [10][11]. - She acknowledges that many of her significant research ideas originated from her students, highlighting the importance of fostering an environment where innovative ideas can flourish [11]. Group 3: Personal Insights and Interests - Bertozzi expresses her passion for music, drawing parallels between music and science in terms of creativity and collaboration. She plays bass guitar and has formed a band with fellow scientists, showcasing her multifaceted interests [3][13][14]. - Her upbringing and family support played a crucial role in her scientific journey, as her father encouraged her and her sisters to pursue their interests in science despite societal stereotypes [10].

Group 1: Clinical Trials and Collaborations - The company Henlius (Shanghai Henlius Biopharmaceutical) is collaborating with Carolyn Bertozzi's team to initiate the first human clinical trial next year [2][7] - The therapy being developed is a dual-function sialidase fusion protein therapy aimed at targeting cancer cells [7] Group 2: Scientific Breakthroughs - Carolyn Bertozzi has made significant breakthroughs in bioorthogonal chemistry, which allows for the tracking and modification of specific biomolecules without disrupting natural biological processes [6] - The developed antibody drug targets sialic acid on cancer cells, enhancing the immune system's ability to recognize and eliminate these cells [5][6] Group 3: Impact on Cancer Treatment - The immune therapy developed by Bertozzi's team has the potential to cure certain types of cancer, such as melanoma and lung cancer, which have higher mutation rates and more receptors on their surface [6] - The advancements in cancer immunotherapy are being referred to as a "penicillin moment" for cancer treatment, indicating a significant breakthrough in the field [2]